Toxicity Management with Trastuzumab Deruxtecan in HER2+ Metastatic Colorectal Cancer

Video

Deanna Griffie, MSN, AGNP-BC, shares how common toxicities in patients with HER2+ mCRC being treated with trastuzumab deruxtecan are treated at her clinic.

Recent Videos
4 experts in this video
4 experts in this video
Future research will aim to assess the efficacy of PIPAC-MMC plus systemic therapy vs systemic therapy alone in patients with peritoneal tumors.
Although small incision surgery may serve as a conduit to deliver PIPAC-MMC, it may confer benefits in the staging and treatment of peritoneal tumors.
Patients with peritoneal metastases were historically associated with limited survival and low consideration for clinical trials.
5 experts in this video
4 experts in this video
5 experts in this video
4 experts in this video
5 experts in this video
Related Content